目的:观察改良长蛇灸治疗阳虚型失眠的临床疗效。方法:将74例阳虚型失眠患者采用随机数字表法分为改良长蛇灸联合西药组和单纯西药组。西药给予右佐匹克隆片,每晚3 mg。改良长蛇灸每周治疗2次,单次时间为1小时。两组均治疗4周,随访1个...目的:观察改良长蛇灸治疗阳虚型失眠的临床疗效。方法:将74例阳虚型失眠患者采用随机数字表法分为改良长蛇灸联合西药组和单纯西药组。西药给予右佐匹克隆片,每晚3 mg。改良长蛇灸每周治疗2次,单次时间为1小时。两组均治疗4周,随访1个月。主要结局为匹兹堡睡眠质量指数(PSQI);次要结局为失眠严重程度指数(ISI)、焦虑自评量表(SAS)、抑郁自评量表(SDS)、疲劳严重程度量表(FSS)、中医证候积分、西药用量情况、不良事件。结果:治疗后,两组PSQI、ISI、SAS、SDS、FSS和中医证候积分均较治疗前明显改善(P P P P > 0.05),但随访1月后治疗组明显优于对照组(P Objective: To observe the clinical effects of enhanced long snake moxibustion on Yang deficiency insomnia. Methods: 74 participants of Yang deficiency insomnia were divided into enhanced long snake moxibustion combined with western medicine group and simple western medicine group. The Western medicine administered was dexzopiclone tablets, 3 mg per night. Enhanced long snake moxibustion was applied twice a week for 1 hour each session. Both groups were treated for 4 weeks with a 1-month follow-up. The primary outcome was the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Insomnia Severity Index (ISI), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Fatigue Severity Scale (FSS), Traditional Chinese Medicine (TCM) syndrome score, dosage of Western medicine, and adverse events. Results: Following treatment, PSQI, ISI, SAS, SDS, FSS, and TCM syndrome scores significantly improved compared to baseline (P P P P > 0.05), but the treatment group showed significant improvement over the control group at 1-month follow-up (P < 0.05). The dosage of Western medicine decreased in the treatment group over the 1-month follow-up period. Conclusion: Enhanced long snake moxibustion effectively alleviates Yang deficiency insomnia, anxiety, depression, fatigue, and TCM syndromes with sustained efficacy and high safety.展开更多
目的:评估区域医联体内心衰专科联盟临床同质化管理运行两年来的成效。方法:回顾性分析专科联盟成立前后(2020年 vs 2022年)各成员单位的总体业务量,以某家下层单位为例,对比分析该单位总体业务水平,然后根据心衰住院患者人数(n = 312 v...目的:评估区域医联体内心衰专科联盟临床同质化管理运行两年来的成效。方法:回顾性分析专科联盟成立前后(2020年 vs 2022年)各成员单位的总体业务量,以某家下层单位为例,对比分析该单位总体业务水平,然后根据心衰住院患者人数(n = 312 vs n = 437)分析其远程会诊人次、上转人次、次均住院天数、次均住院费用、药占比和患者满意度。结果:与2020年相比,2022年各级医院的门诊人次、住院人次、双向转诊量明显增加;下沉单位的总体门诊人次、住院人次分别增长21.98%和34.04%、双向转诊增长约40%。比较两年的心衰住院患者数据,与2020年相比,2022年该单位心衰住院患者的远程会诊增长率达66.67%,上转人次占比下降11.85%。此外,专科联盟成立后,心衰患者次均住院天数和药占比显著下降(均P < 0.05),次均住院费用明显减少(P < 0.05);患者就医满意度明显增加(P < 0.05)。结论:区域医联体心衰专科联盟临床同质化管理取得初步成效,继续加强优势资源下沉,吸收更多医疗单位致力于为患者提供更多医疗保障。展开更多
文摘目的:观察改良长蛇灸治疗阳虚型失眠的临床疗效。方法:将74例阳虚型失眠患者采用随机数字表法分为改良长蛇灸联合西药组和单纯西药组。西药给予右佐匹克隆片,每晚3 mg。改良长蛇灸每周治疗2次,单次时间为1小时。两组均治疗4周,随访1个月。主要结局为匹兹堡睡眠质量指数(PSQI);次要结局为失眠严重程度指数(ISI)、焦虑自评量表(SAS)、抑郁自评量表(SDS)、疲劳严重程度量表(FSS)、中医证候积分、西药用量情况、不良事件。结果:治疗后,两组PSQI、ISI、SAS、SDS、FSS和中医证候积分均较治疗前明显改善(P P P P > 0.05),但随访1月后治疗组明显优于对照组(P Objective: To observe the clinical effects of enhanced long snake moxibustion on Yang deficiency insomnia. Methods: 74 participants of Yang deficiency insomnia were divided into enhanced long snake moxibustion combined with western medicine group and simple western medicine group. The Western medicine administered was dexzopiclone tablets, 3 mg per night. Enhanced long snake moxibustion was applied twice a week for 1 hour each session. Both groups were treated for 4 weeks with a 1-month follow-up. The primary outcome was the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Insomnia Severity Index (ISI), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Fatigue Severity Scale (FSS), Traditional Chinese Medicine (TCM) syndrome score, dosage of Western medicine, and adverse events. Results: Following treatment, PSQI, ISI, SAS, SDS, FSS, and TCM syndrome scores significantly improved compared to baseline (P P P P > 0.05), but the treatment group showed significant improvement over the control group at 1-month follow-up (P < 0.05). The dosage of Western medicine decreased in the treatment group over the 1-month follow-up period. Conclusion: Enhanced long snake moxibustion effectively alleviates Yang deficiency insomnia, anxiety, depression, fatigue, and TCM syndromes with sustained efficacy and high safety.
文摘目的:评估区域医联体内心衰专科联盟临床同质化管理运行两年来的成效。方法:回顾性分析专科联盟成立前后(2020年 vs 2022年)各成员单位的总体业务量,以某家下层单位为例,对比分析该单位总体业务水平,然后根据心衰住院患者人数(n = 312 vs n = 437)分析其远程会诊人次、上转人次、次均住院天数、次均住院费用、药占比和患者满意度。结果:与2020年相比,2022年各级医院的门诊人次、住院人次、双向转诊量明显增加;下沉单位的总体门诊人次、住院人次分别增长21.98%和34.04%、双向转诊增长约40%。比较两年的心衰住院患者数据,与2020年相比,2022年该单位心衰住院患者的远程会诊增长率达66.67%,上转人次占比下降11.85%。此外,专科联盟成立后,心衰患者次均住院天数和药占比显著下降(均P < 0.05),次均住院费用明显减少(P < 0.05);患者就医满意度明显增加(P < 0.05)。结论:区域医联体心衰专科联盟临床同质化管理取得初步成效,继续加强优势资源下沉,吸收更多医疗单位致力于为患者提供更多医疗保障。
